Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage.

Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M.

J Hum Hypertens. 2014 Feb;28(2):74-9. doi: 10.1038/jhh.2013.55. Epub 2013 Jun 27. Review.

PMID:
23803592
2.

[Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].

Jovanović DB, Jovović Dj, Varagić J, Dimitrijević J, Dragojlović Z, Djukanović L.

Srp Arh Celok Lek. 2002 Mar-Apr;130(3-4):73-80. Serbian.

3.

Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.

Yoshida S, Ishizawa K, Ayuzawa N, Ueda K, Takeuchi M, Kawarazaki W, Fujita T, Nagase M.

Clin Exp Nephrol. 2014 Aug;18(4):593-9. doi: 10.1007/s10157-013-0893-6. Epub 2013 Oct 24.

PMID:
24154707
4.

N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress.

Mattace Raso G, Simeoli R, Russo R, Santoro A, Pirozzi C, d'Emmanuele di Villa Bianca R, Mitidieri E, Paciello O, Pagano TB, Orefice NS, Meli R, Calignano A.

Pharmacol Res. 2013 Oct;76:67-76. doi: 10.1016/j.phrs.2013.07.007. Epub 2013 Aug 2.

PMID:
23917217
5.

Progression of hypertension and kidney disease in aging fawn-hooded rats is mediated by enhanced influence of renin-angiotensin system and suppression of nitric oxide system and epoxyeicosanoids.

Doleželová Š, Jíchová Š, Husková Z, Vojtíšková A, Kujal P, Hošková L, Kautzner J, Sadowski J, Červenka L, Kopkan L.

Clin Exp Hypertens. 2016;38(7):644-651. Epub 2016 Sep 26.

PMID:
27669111
6.

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.

Hallow KM, Lo A, Beh J, Rodrigo M, Ermakov S, Friedman S, de Leon H, Sarkar A, Xiong Y, Sarangapani R, Schmidt H, Webb R, Kondic AG.

Am J Physiol Regul Integr Comp Physiol. 2014 May;306(9):R647-62. doi: 10.1152/ajpregu.00039.2013. Epub 2014 Feb 5.

7.

Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.

Karalliedde J, Viberti G.

J Hum Hypertens. 2006 Apr;20(4):239-53. Review.

PMID:
16452996
8.

[Are all antihypertensive drugs renoprotective?].

Wolf S, Risler T.

Herz. 2004 May;29(3):248-54. Review. German.

PMID:
15167950
9.

Cellular mediators of renal vascular dysfunction in hypertension.

Ponnuchamy B, Khalil RA.

Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R1001-18. doi: 10.1152/ajpregu.90960.2008. Epub 2009 Feb 18. Review.

10.

Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.

Chung S, Park CW, Shin SJ, Lim JH, Chung HW, Youn DY, Kim HW, Kim BS, Lee JH, Kim GH, Chang YS.

Nephrol Dial Transplant. 2010 Feb;25(2):389-99. doi: 10.1093/ndt/gfp472. Epub 2009 Sep 11.

PMID:
19749146
11.

Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system.

Viazzi F, Leoncini G, Pontremoli R.

High Blood Press Cardiovasc Prev. 2013 Dec;20(4):273-82. doi: 10.1007/s40292-013-0027-y. Epub 2013 Oct 4. Review.

12.

Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.

Liu XP, Pang YJ, Zhu WW, Zhao TT, Zheng M, Wang YB, Sun ZJ, Sun SJ.

Clin Exp Pharmacol Physiol. 2009 Mar;36(3):287-96. doi: 10.1111/j.1440-1681.2008.05078.x. Epub 2008 Nov 10.

PMID:
19018797
13.

Renal protection with angiotensin receptor blockers: where do we stand.

Schmieder RE, Ruilope LM, Barnett AH.

J Nephrol. 2011 Sep-Oct;24(5):569-80. doi: 10.5301/JN.2011.6445. Review.

PMID:
21404225
14.

Renal oxidative stress, oxygenation, and hypertension.

Palm F, Nordquist L.

Am J Physiol Regul Integr Comp Physiol. 2011 Nov;301(5):R1229-41. doi: 10.1152/ajpregu.00720.2010. Epub 2011 Aug 10. Review.

15.

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.

Lambers Heerspink HJ, Perkovic V, de Zeeuw D.

J Hypertens. 2009 Dec;27(12):2321-31. doi: 10.1097/HJH.0b013e3283310f92. Review.

PMID:
19727007
16.

Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage.

Grandi AM, Maresca AM.

Cardiovasc Hematol Agents Med Chem. 2006 Jul;4(3):219-28. Review.

PMID:
16842207
17.

Hypertension: renin-angiotensin-aldosterone system alterations.

Te Riet L, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH.

Circ Res. 2015 Mar 13;116(6):960-75. doi: 10.1161/CIRCRESAHA.116.303587. Review.

18.
19.

Barnidipine ameliorates the vascular and renal injury in L-NAME-induced hypertensive rats.

Alp Yildirim FI, Eker Kizilay D, Ergin B, Balci Ekmekçi Ö, Topal G, Kucur M, Demirci Tansel C, Uydeş Doğan BS.

Eur J Pharmacol. 2015 Oct 5;764:433-42. doi: 10.1016/j.ejphar.2015.07.033. Epub 2015 Jul 14.

PMID:
26187312
20.

Renal protection and antihypertensive drugs: current status.

Salvetti A, Mattei P, Sudano I.

Drugs. 1999 May;57(5):665-93. Review.

PMID:
10353294

Supplemental Content

Support Center